-
Loading metrics
Open Access
Peer-reviewed
Research Article
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
-
S. Di Matteo,
Roles Data curation, Formal analysis, Investigation, Methodology, Software, Supervision, Visualization, Writing – original draft
Affiliation Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
⨯ -
L. Nevi ,
Contributed equally to this work with: L. Nevi, D. Costantini
Roles Methodology
Affiliation Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
⨯ -
D. Costantini ,
Contributed equally to this work with: L. Nevi, D. Costantini
Roles Methodology
Affiliation Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
⨯ -
D. Overi,
Roles Methodology
Affiliation Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy
⨯ -
G. Carpino,
Roles Methodology
Affiliation Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Rome, Italy
⨯ -
S. Safarikia,
Roles Methodology
Affiliation Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
⨯ -
F. Giulitti,
Roles Data curation, Formal analysis, Investigation, Methodology, Software
Affiliation Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Rome, Italy
⨯ -
C. Napoletano,
Roles Methodology
Affiliation Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
⨯ -
E. Manzi,
Roles Resources
Affiliation Gastroenterology Unit, Regina Elena National Cancer Institute, Rome, Italy
⨯ -
A. M. De Rose,
Roles Resources
Affiliation Hepatobiliary Unit, Catholic University of the Sacred Heart School of Medicine, Rome, Italy
⨯ -
F. Melandro,
Roles Resources
Affiliation Department of General Surgery and Organ Transplantation, Sapienza University of Rome, Rome, Italy
⨯ -
M. Bragazzi,
Roles Resources
Affiliation Medical-Surgical and Biotechnologies Sciences, Polo Pontino, Sapienza University of Rome, Rome, Italy
⨯ -
P. B. Berloco,
Roles Resources
Affiliation Department of General Surgery and Organ Transplantation, Sapienza University of Rome, Rome, Italy
⨯ -
F. Giuliante,
Roles Resources
Affiliation Hepatobiliary Unit, Catholic University of the Sacred Heart School of Medicine, Rome, Italy
⨯ -
G. Grazi,
Roles Resources
Affiliation Gastroenterology Unit, Regina Elena National Cancer Institute, Rome, Italy
⨯ -
A. Giorgi,
Roles Visualization
Affiliation Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
⨯ -
V. Cardinale,
Roles Resources
Affiliation Medical-Surgical and Biotechnologies Sciences, Polo Pontino, Sapienza University of Rome, Rome, Italy
⨯ -
L. Adorini,
Roles Supervision, Visualization
Affiliation Intercept Pharmaceuticals, New York, New York, United States of America
⨯ -
E. Gaudio,
Roles Funding acquisition
Affiliation Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy
⨯ - [ ... ],
-
D. Alvaro
Roles Conceptualization, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: domenico.alvaro@uniroma1.it
Affiliation Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
⨯ - [ view all ]
- [ view less ]
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
- S. Di Matteo,
- L. Nevi,
- D. Costantini,
- D. Overi,
- G. Carpino,
- S. Safarikia,
- F. Giulitti,
- C. Napoletano,
- E. Manzi,
- A. M. De Rose
- Published: January 24, 2019
- https://doi.org/10.1371/journal.pone.0210077